Hofbauer LC and Heufelder AE |
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. |
2001 |
Arthritis Rheum. |
pmid:11229454
|
Leach RJ et al. |
The genetics of Paget's disease of the bone. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11231972
|
Hofbauer LC and Heufelder AE |
[Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. |
2001 |
Dtsch. Med. Wochenschr. |
pmid:11233883
|
Bolon B et al. |
Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. |
2001 |
Mol. Ther. |
pmid:11237676
|
Sasaki N et al. |
Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. |
2001 |
Nephrol. Dial. Transplant. |
pmid:11239019
|
Takeuchi T et al. |
Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. |
2001 |
Biochem. Pharmacol. |
pmid:11239501
|
Mori K et al. |
Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. |
2001 |
Cell. Immunol. |
pmid:11243701
|
Michigami T et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. |
2001 |
Cancer Res. |
pmid:11245477
|
Wada N et al. |
Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. |
2001 |
J. Periodont. Res. |
pmid:11246705
|
Lories RJ and Luyten FP |
Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. |
2001 |
Clin. Rheumatol. |
pmid:11254237
|